BIOORG3.14 LLC

Biotech · Private

BG-148, a small molecule oral insulin replacement for glycemic control in diabetes

Grants
$2.2M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Evaluation of a therapeutic strategy to combat osteoarthritis$223,898
Federal grantDepartment of Health and Human Services · Phase I · Evaluation of a therapeutic strategy to combat osteoarthritis$223,898
Federal grantDepartment of Health and Human Services · Phase II · A diabetes pill to replace insulin injections$223,848
Federal grantDepartment of Health and Human Services · Phase II · A diabetes pill to replace insulin injections$740,045
Federal grantDepartment of Health and Human Services · Phase II · A diabetes pill to replace insulin injections$759,882
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1289PIPA LLC——
1290Aurora Oncology, Inc.——
1291RIDGELINE THERAPEUTICS LLC——
1292BIOORG3.14 LLC——
1293SUNOMIX THERAPEUTICS——
1294ImmunoTarget Therapeutics, Inc.——
1295MEDISYNERGICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.